DataSheet_1_Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer.xlsx by Xinqing Lin (9659243)

“…Background<p>Checkpoint inhibitor-related pneumonitis (CIP) is a potentially fatal immune-related adverse event that occurs during treatment with immune checkpoint inhibitors (ICIs). …”

Table_1_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.doc by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Image_3_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.tif by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Data_Sheet_1_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.docx by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Image_4_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.tif by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Image_2_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.tif by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Image_1_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.tif by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Advanced assessment of ductile fracture in steel by X-ray computed tomography by Fabien Léonard (463224)

Manager's Discretionary Power and Comparability of Financial Reports: An Analysis of the Regulatory Transition Process in Brazilian Accounting by Alex Mussoi Ribeiro (12830273)

The proposed mechanism whereby PPi protects against early electrical failure in the course of LDVF. by Junko Shibayama (387144)

Chronic EtOH exposure alters prefrontal neurotrophin levels. by Gina M. Fernandez (2547475)

“…(B) Mean concentration levels (pg/mg) for β-NGF in the prefrontal cortex by Age and Treatment group, collapsed across time-points. There was a main effect of Treatment [E, p<0.05], with CET rats displaying significantly decreased levels of β-NGF in the prefrontal cortex. …”

DataSheet1_Optical properties of graphene oxide.docx by Talia Tene (15443348)

“…Our findings indicate that exposing the GO sample to a drying time of up to 120 h at 80°C can lead to a reduction in the optical bandgap, decreasing it from 4.09 to 2.76 eV. …”

Depths of computation inferred from the maximally overlapping strategies for every row and for all stimuli. by Joseph Snider (640571)

“…The points form an upper envelope whose edge has a negative slope on the right side of every plot, reflecting the decreasing number of rows to stimulus end. …”

Thirty-year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes by Michael Fang (9708234)

“…</p> <p><b>Results: </b>From 1988-1994 to 2011-2018, there was a significant decrease in the prevalence of albuminuria (38.9 to 18.7%, p-for-trend<0.001), but no change in the prevalence of reduced eGFR (7.5 to 9.9%, p-for-trend=0.30), retinopathy (1988-1994 to 1999-2008 only; 13.2 to 12.1%, p-for-trend=0.86), or self-reported cardiovascular disease (19.0 to 16.5%, p-for-trend=0.64). …”

TolB is crucial for <i>P. aeruginosa</i> resistance and persistence. by Alessandra Lo Sciuto (610616)

“…(B) Lytic effect of SDS (0–5%), measured as decrease in cell suspension turbidity (OD₆₀₀), on PAO1 wild-type cells (WT, filled circles), TolB-deficient mutant cells (<i>tolB</i>, open diamonds) and TolB-proficient mutant cells (<i>tolB</i> TolB⁺, filled diamonds). …”

Expression of Sox2, Sox10, Gata3, Prox1 and Peripherin during primary auditory neuron development and maturation. by Koji Nishimura (2077804)

“…At E10.5, Sox10 was downregulated as neuroblasts delaminated from the otocyst. …”

Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes: Supplementary materials by William L Herring (14039541)

“…The fibrosis worsening profile reduced predicted 10-year LRC rates (F1:</p> <p>1.9%; F2: 6.5%; F3: 19.1%; F4/CC: 55.0%) more than the resolution and fibrosis improvement profiles</p> <p>(F1: 2.6%/2.6%; F2: 8.5%/8.3%; F3: 23.3%/23.0%; F4/CC: NA/59.0%). …”

Secondary metabolites from <i>Gentiana cruciata</i> L. and their anti-inflammatory and analgesic activities by Rima Konya (14075753)

“…<p>A previously unreported secoiridoid glycoside, cruciatoside (<b>1</b>) was isolated from the aerial parts of <i>Gentiana cruciata</i> L. along with ten known compounds eustomoside (<b>2</b>), eustomorusside (<b>3</b>), gentiopicroside (<b>4</b>), 6'-<i>O</i>-β-D-glucopyranosyl gentiopicroside (<b>5</b>), loganic acid (<b>6</b>), isoorientin (<b>7</b>), isovitexin (<b>8</b>), isovitexin 2''<i>-(E)-</i>ferulate (<b>9</b>), mangiferin (<b>10</b>), and 2-methyl-inositol (<b>11</b>). …”

MPs^PPARα+/+-induced EPC differentiation and <i>in vitro</i> angiogenesis of mature ECs involve NF-κB pathway activation. by Tarek Benameur (196206)

“…<p>(<b>A</b>) Western blot showing that MPs^PPARα+/+ induced I-κB phosphorylation on activator sites (Ser32/36) in EPCs, indicating that NF-κB pathway is activated. …”

DNMT1-mediated demethylation of lncRNA MEG3 promoter suppressed breast cancer progression by repressing Notch1 signaling pathway by Tingting Pan (4735617)

“…Functionally, treatment of breast cancer cells with the DNA methylation inhibitor 5-AzadC as well as silencing of DNA methyltransferase-1 (DNMT1) could decrease the abnormal hypermethylation of the MEG3 promoter, reverse MEG3 expression, inhibit cell proliferation and promote cell apoptosis. …”